Skip to main content
Journal cover image

Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.

Publication ,  Journal Article
Mohamed, AF; Zhang, J; Johnson, FR; Lomon, ID; Malvolti, E; Townsend, R; Ostgren, CJ; Parhofer, KG
Published in: Diabetes Metab
October 2013

AIMS: The aim of the study was to quantify patient preferences for outcomes associated with oral antidiabetic medications (OAMs) in Sweden and Germany through a discrete-choice experiment. METHODS: Adults taking OAMs who had a self-reported physician's diagnosis of type 2 diabetes mellitus (T2DM) made a series of nine choices between pairs of hypothetical profiles. Each profile had a predefined range of attributes: blood glucose control, frequency of mild-to-moderate hypoglycaemia, annual severe hypoglycaemic events, annual weight gain, pill burden and frequency of administration, and cost. Choice questions were based on an experimental design with known statistical properties. Bivariate probit analysis estimated the probabilities of choice of medication administration from patient characteristics and, conditional on that choice, preferences for treatment outcomes. RESULTS: The final sample consisted of 188 Swedish and 195 German patients. For both countries, weight gain was the most important attribute, followed by blood glucose control. Avoiding a 5-kg weight gain was 1.5 times more important in Sweden and 2.3 times more important in Germany than achieving moderate blood glucose control, thereby, suggesting that blood glucose control is relatively more important to Swedish than to German patients. Least important outcomes were the number of daily pills (Sweden) and frequency of mild-to-moderate hypoglycaemia (Germany). CONCLUSION: Patients in both Sweden and Germany preferred OAMs not associated with weight gain.

Duke Scholars

Published In

Diabetes Metab

DOI

EISSN

1878-1780

Publication Date

October 2013

Volume

39

Issue

5

Start / End Page

397 / 403

Location

France

Related Subject Headings

  • Weight Gain
  • Treatment Outcome
  • Sweden
  • Surveys and Questionnaires
  • Self Care
  • Patient Preference
  • Middle Aged
  • Medication Adherence
  • Male
  • Hypoglycemic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mohamed, A. F., Zhang, J., Johnson, F. R., Lomon, I. D., Malvolti, E., Townsend, R., … Parhofer, K. G. (2013). Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab, 39(5), 397–403. https://doi.org/10.1016/j.diabet.2013.06.001
Mohamed, A. F., J. Zhang, F. R. Johnson, I Duprat Lomon, E. Malvolti, R. Townsend, C. J. Ostgren, and K. G. Parhofer. “Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.Diabetes Metab 39, no. 5 (October 2013): 397–403. https://doi.org/10.1016/j.diabet.2013.06.001.
Mohamed AF, Zhang J, Johnson FR, Lomon ID, Malvolti E, Townsend R, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013 Oct;39(5):397–403.
Mohamed, A. F., et al. “Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.Diabetes Metab, vol. 39, no. 5, Oct. 2013, pp. 397–403. Pubmed, doi:10.1016/j.diabet.2013.06.001.
Mohamed AF, Zhang J, Johnson FR, Lomon ID, Malvolti E, Townsend R, Ostgren CJ, Parhofer KG. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013 Oct;39(5):397–403.
Journal cover image

Published In

Diabetes Metab

DOI

EISSN

1878-1780

Publication Date

October 2013

Volume

39

Issue

5

Start / End Page

397 / 403

Location

France

Related Subject Headings

  • Weight Gain
  • Treatment Outcome
  • Sweden
  • Surveys and Questionnaires
  • Self Care
  • Patient Preference
  • Middle Aged
  • Medication Adherence
  • Male
  • Hypoglycemic Agents